» Articles » PMID: 33053665

Nrf2 in Neoplastic and Non-Neoplastic Liver Diseases

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Oct 15
PMID 33053665
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Activation of the Keap1/Nrf2 pathway, the most important cell defense signal, triggered to neutralize the harmful effects of electrophilic and oxidative stress, plays a crucial role in cell survival. Therefore, its ability to attenuate acute and chronic liver damage, where oxidative stress represents the key player, is not surprising. On the other hand, while Nrf2 promotes proliferation in cancer cells, its role in non-neoplastic hepatocytes is a matter of debate. Another topic of uncertainty concerns the nature of the mechanisms of Nrf2 activation in hepatocarcinogenesis. Indeed, it remains unclear what is the main mechanism behind the sustained activation of the Keap1/Nrf2 pathway in hepatocarcinogenesis. This raises doubts about the best strategies to therapeutically target this pathway. In this review, we will analyze and discuss our present knowledge concerning the role of Nrf2 in hepatic physiology and pathology, including hepatocellular carcinoma. In particular, we will critically examine and discuss some findings originating from animal models that raise questions that still need to be adequately answered.

Citing Articles

Catechins: Protective mechanism of antioxidant stress in atherosclerosis.

Sheng Y, Sun Y, Tang Y, Yu Y, Wang J, Zheng F Front Pharmacol. 2023; 14:1144878.

PMID: 37033663 PMC: 10080012. DOI: 10.3389/fphar.2023.1144878.


SOCS1 Deficiency Promotes Hepatocellular Carcinoma via SOCS3-Dependent CDKN1A Induction and NRF2 Activation.

Khan M, Boufaied N, Yeganeh M, Kandhi R, Petkiewicz S, Sharma A Cancers (Basel). 2023; 15(3).

PMID: 36765862 PMC: 9913612. DOI: 10.3390/cancers15030905.


Novel NRF2-activated cancer treatments utilizing synthetic lethality.

Baird L, Kensler T, Yamamoto M IUBMB Life. 2022; 74(12):1209-1231.

PMID: 36200139 PMC: 10092255. DOI: 10.1002/iub.2680.


p62 Promotes Survival and Hepatocarcinogenesis in Mice with Liver-Specific NEMO Ablation.

Kondylis V, Schneider F, Schorn F, Oikonomou N, Straub B, Werner S Cancers (Basel). 2022; 14(10).

PMID: 35626041 PMC: 9139637. DOI: 10.3390/cancers14102436.


Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents.

Selvaggi F, Catalano T, Cotellese R, Aceto G Cancers (Basel). 2022; 14(8).

PMID: 35454818 PMC: 9024538. DOI: 10.3390/cancers14081912.


References
1.
Zhou S, Ye W, Duan X, Zhang M, Wang J . The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. Dig Dis Sci. 2013; 58(6):1615-26. DOI: 10.1007/s10620-012-2537-1. View

2.
Cuadrado A, Manda G, Hassan A, Alcaraz M, Barbas C, Daiber A . Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. 2018; 70(2):348-383. DOI: 10.1124/pr.117.014753. View

3.
Cleary S, Jeck W, Zhao X, Chen K, Selitsky S, Savich G . Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology. 2013; 58(5):1693-702. PMC: 3830584. DOI: 10.1002/hep.26540. View

4.
Qu Q, Liu J, Zhou H, Klaassen C . Nrf2 protects against furosemide-induced hepatotoxicity. Toxicology. 2014; 324:35-42. DOI: 10.1016/j.tox.2014.02.008. View

5.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View